Products for Research Use Only
RegisterLogin

Lasmotinib

CAT: 0804-HY-153857-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153857-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lasmotinib (PHI-101) is a FLT3 and CHK2 inhibitor. Lasmotinib potently inhibits FLT3 single activating mutations (ITD or TKD mutants) and has inhibitory activity against FLT3 double (ITD/D835Y or ITD/F691L) and triple (ITD/D835Y/F691L) resistance mutations. Lasmotinib synergizes with Venetoclax or Azacytidine to inhibit leukemia. Lasmotinib exhibits anticancer activity against ovarian and breast cancer[1][2][3][4].
CAS Number
2127107-15-5
Product Name Alternative
PHI-101
UNSPSC
12352005
Target
Checkpoint Kinase (Chk) ; FLT3
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/phi-101.html
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC(NC1=C(SC(C#CC2=CC(F)=CC=C2)=C1)C(N[C@H]3CCCNC3)=O)=O
Molecular Formula
C19H19FN4O2S
Molecular Weight
386.44
References & Citations
[1]Nam K Y, et al. PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia[J]. Blood, 2020, 136: 28.|[2]Sung G J, Kim K A, Nam K Y, et al. Evaluation of Synergistic Anti-Leukemic Efficacy of PHI-101 in Preclinical Model of FLT3-ITD Acute Myeloid Leukemia. Blood, 2023, 142: 5949. |[3]Han J H J, Kim K T, Im J, et al. PHI-101, a potent and novel inhibitor of CHK2 in ovarian and breast cancer cells. Cancer Research, 2021, 81 (13_Supplement) : 1461-1461.|[4]Hwang H, Sung G J, Kim K A, et al. PHI-101 synergizes with chemotherapy and venetoclax in preclinical models of acute myeloid leukemia. Cancer Research, 2024, 84 (6_Supplement) : 7153-7153.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Chk2

Alternative Products

CatalogName
A24191-50Lasmotinib (PHI-101) 50mg
A24191-10Lasmotinib (PHI-101) 10mg
A24191-5Lasmotinib (PHI-101) 5mg
A24191-1Lasmotinib (PHI-101) 1mg

Popular Products